Related Experiment Videos
Amélie Mallet1, De Calbiac Ombline1, Marie Robert1
1Département d'oncologie médicale, Institut de cancérologie de l'Ouest - René Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France.
Abstract:
The emergence of a new tumor entity called HER2-low breast cancer leads us to reconsider therapeutic indications in patients whose tumors were usually considered as luminal or triple negative. The development of antibody-drug conjugates (ADCs) allows using HER2 as a vector of a cytoxic drug with significant clinical efficacy in breast cancer with low HER2 expression. Trastuzumab deruxtecan monotherapy is currently evaluated in phase III trials in HER2-low patients, but also in combination in earlier phase studies. Many ADCs are in development, with highly anticipated results. The toxicities of these various ADCs seem manageable and compatible with prolonged administration. Her2-low breast cancer subtype may benefit from dedicated therapeutic strategies in the next few years.
Insights
HER2-low breast cancer, previously untreatable, can now benefit from antibody-drug conjugates (ADCs). These targeted therapies show efficacy and manageable toxicity, offering new hope for patients with this subtype.
Area of Science:
- Oncology
- Pharmacology
Background:
- HER2-low breast cancer represents a newly defined subtype.
- Traditionally, these tumors were classified as luminal or triple-negative, lacking targeted therapies.
- The human epidermal growth factor receptor 2 (HER2) is a target for novel therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of antibody-drug conjugates (ADCs) in HER2-low breast cancer.
- To explore the potential of HER2 as a target for drug delivery in this patient population.
- To discuss the implications of ADCs for future therapeutic strategies in HER2-low breast cancer.
Main Methods:
- Review of current clinical trials and development of ADCs targeting HER2.
- Analysis of efficacy data for trastuzumab deruxtecan monotherapy and combination studies.
- Assessment of toxicity profiles of various ADCs in HER2-low breast cancer patients.
Main Results:
- ADCs demonstrate significant clinical efficacy in HER2-low breast cancer.
- Trastuzumab deruxtecan is under investigation in Phase III trials for HER2-low breast cancer.
- Emerging ADCs show promising results and manageable toxicity profiles.
Conclusions:
- HER2-low breast cancer may benefit from dedicated therapeutic strategies.
- ADCs offer a promising new avenue for treating HER2-low breast cancer.
- Continued development of ADCs is anticipated to yield further advancements in patient care.